OVID - NASDAQ
Ovid Therapeutics Inc.
$2.46
+2.6%Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
At a Glance
Live SnapshotOvid Therapeutics Inc. Management Team
Mr. Jeffrey A. Rona
Chief Business and Financial Officer
Compensation
$712,228
Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.
Chief Executive Officer & Chairman
Compensation
$931,422
Dr. Manal Morsy M.B.A., M.D., PH.D.
Chief Regulatory Officer
Mr. Zhong Zhong Ph.D.
Chief Scientific Officer
Dr. Toshiya Nishi D.V.M.
Head of Epilepsy Research
Ms. Margaret Alexander
President & Chief Operating Officer
Compensation
$729,727
Dr. Julia Tsai Ph.D.
Senior Vice President of Clinical Development
Ms. Victoria Fort
Senior Vice President of Corporate Affairs & Corporate Strategy
Dr. Dirk Haasner
Senior Vice President of Global Manufacturing & CMC QA
Compensation
$416,952
Mr. Tom Parry
Vice President of Research and Early Development
Ovid Therapeutics Inc. Insider Positioning
During the last 12 months, insiders have purchased $66K and sold $29K worth of OVID shares, resulting in $37K of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
47.3K
66.27K
20.2K
29.29K
+37K
+$37K
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Levin Jeremy M
Director, Officer: Ceo
$66K
Top Sellers
Alexander Margaret A.
Director, Officer: President And Ceo
$17K
Rona Jeffrey A
Officer: Cbfo
$12K
Insider Activity Analysis
Net Insider Sentiment
Positive insider sentiment with $37K net buying. Buying activity substantially exceeds selling, indicating insider confidence.
Buy/Sell Ratio
Strong buy/sell ratio. Buying is at least double the selling activity, suggesting robust insider confidence.
Insider Participation
2 insider sellers vs. 1 buyers. More insiders selling than buying suggests cautious or negative sentiment.
SEC Filings
OVID - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 27, 2026 | December 31, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | November 07, 2025 | December 11, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | May 22, 2025 | December 31, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | April 24, 2024 | April 24, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 27, 2023 | June 08, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 09, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 30, 2021 | June 10, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 24, 2020 | June 04, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 24, 2019 | June 07, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 24, 2018 | June 06, 2018 | 2018 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.